Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
about
Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myelomaNovel therapeutic strategies for multiple myelomaInhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathwaysActivity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell linesMicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancyIdentification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Emerging pathways as individualized therapeutic target of multiple myeloma.AKT as a therapeutic target in multiple myeloma.Novel investigational drugs active as single agents in multiple myeloma.Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.Signaling Pathways and Emerging Therapies in Multiple Myeloma.Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
P2860
Q27700745-F54C9928-D936-4055-AB63-34E341A121BDQ28081590-52590158-9079-4A8A-880E-79A0C6C72C9DQ33875590-07E6F97D-BC66-4199-8A5B-5BDC4EE46EEAQ34075096-4F027F08-9EB7-4EF0-941E-0D669BD0DC47Q34158470-D26E25FA-972B-4336-BD00-F067AADB51FDQ35236076-380226DD-6A7B-41BF-938B-0C1247C4293CQ35594600-3A8E6178-BF16-4D5B-8744-527DF39D745FQ35615252-3D5A30A5-BE22-4DFF-B4AC-9715FEBF6F3BQ35667885-4EAAD0AD-D382-43F3-B96E-0A127BCA800AQ36737884-AC5AE691-4E41-467E-9BB3-43B7E00D08B9Q37583378-418DAFE3-9F9E-4AEB-B065-5F8BEFEAA361Q37636618-8777BA32-FD2D-42FF-A49B-230C9FCDF285Q37697253-2CE41F90-67D4-4BE0-8514-01C449E19361Q38112176-B08D4FBC-0807-474B-B9AD-A7CF5D1316C5Q38218256-F28403C3-845F-41C4-8240-0005D063D0A5Q38690290-BC7D005A-19DC-4222-8181-6736D9C0C7F2Q38718211-7154BCA0-19AF-4A26-843E-E22B2903BB63Q38753307-687AFFE5-1F4F-46B4-92AD-D26D7217B773Q38950582-B98BDB77-6C62-413A-BA46-BCF882C08A82Q47094892-396BCE94-F3F1-4AF5-A8F0-E754DC0D11D0Q47618731-DF601183-F2E3-4C95-811E-5A5507050C51Q48263465-9C17307E-9E69-4B65-B996-BF76E3E1E533Q53055574-9EDDBFCE-BB7B-4390-9E76-7CFAE24C9604Q57818334-A9A60B3C-3116-4FAA-9A4E-7CC464D170DD
P2860
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@ast
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@en
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@nl
type
label
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@ast
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@en
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@nl
prefLabel
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@ast
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@en
Anti-myeloma activity of Akt i ...... PI3K/Akt and MEK/ERK pathway.
@nl
P2093
P2860
P1433
P1476
Anti-myeloma activity of Akt i ...... f PI3K/Akt and MEK/ERK pathway
@en
P2093
Jessica Haug
Linda Wellik
Shaji Kumar
Teresa Kimlinger
Timothy Halling
Utkarsh Painuly
Vijay Ramakrishnan
P2860
P304
P356
10.1371/JOURNAL.PONE.0050005
P407
P577
2012-11-21T00:00:00Z